Emerging data suggest Retatrutide , a dual activator targeting both incretin and another hormone, could provide a significant advancement for body loss . Initial patient trials have indicated impressive losses in abdominal tissue, conceivably outperforming current body composition medications . Despite this, further study is needed to fully assess